fda glp-1 warning letters news Issues 30 to Telehealth Firms Over Misleading Compounded Marketing FDA Issues Warning Letters to

Research from National Library of Medicine in 2024 also suggests GLP-1 drugs are linked to adverse gastrointestinal events, including nausea, vomiting, delayed gastric emptying and pancreatitis

However, patients need to increase their resistance and weight-based workouts to combat muscle loss and increased appetite after coming off medication

On average, studies show most people living with obesity lose between 15% and 25% of their body weight after just one year on a GLP-1

Just remembermedication works best alongside healthy habits and guidance from your care team.

The FDA also recommends examining hard clinical endpoints such hepatic decompensations, transplant free survival, and all-cause mortality, although these results are not necessarily needed prior to drug approval given the long length of follow up potentially required

That said, this is still emerging research, and more is needed to fully understand the long-term effects and potential of GLP-1 medications for different populations